Brown Brothers Harriman Investor Services and SimCorp Forge Strategic Alliance to Provide Integrated End-to-End Technology, Data, and Services Solution for Global Asset Managers
28.1.2026 15:00:00 CET | Business Wire | Press Release
Brown Brothers Harriman (BBH), a privately held global financial services firm, and SimCorp, a leading global financial technology company, today announced a new strategic alliance to address the needs of global asset managers requiring an integrated, end-to-end technology, data, and services solution.
Enhancing both firms’ existing offerings, this solution uses BBH Infomediary to integrate SimCorp One’s front and middle office capabilities, including a real-time IBOR managed by SimCorp’s Managed Business Services, with BBH’s fund servicing and custody suite.
BBH Infomediary, BBH’s connectivity and data integration engine, will also enable a unique open architecture model that helps connect clients to third party technologies and service providers.
“For managers seeking to streamline their technology and operations across the entire investment lifecycle, this offering delivers scalability, accelerates data strategies, and allows a sharper focus on investment results,” said Shawn McNinch, Partner at BBH. “In SimCorp, we have found a firm with award-winning technology and a service model that complements our own to provide clients with the best that both firms bring to the market.”
Key benefits include:
- Accelerated transformation and time to value
- Increased oversight and control over operations
- Flexibility to integrate with third parties and retain strategic agility
“We are excited to extend the benefits of our SimCorp One platform further into our clients’ operating model with BBH’s asset servicing and Infomediary data integration capabilities to create an end-to-end solution,” said Oliver Johnson, Chief Revenue Officer at SimCorp. “BBH’s solutions and reputation for service are a great complement to our offering, providing clients with an efficient and open architecture solution.”
The first asset manager to benefit from this combined solution is systematic manager, Quoniam Asset Management, in support of their recently announced UniActive Q ETF launch.
Silke Weiser-Walther, Quoniam’s Chief Operating Officer, said, “We are delighted that two of our valued strategic providers have come together to deliver a more efficient end-to-end workflow. With their support, we can ensure that our innovative ETF products are underpinned by robust infrastructure and real time, accurate data, empowering us to deliver enhanced outcomes for our clients.”
Learn more about the BBH & SimCorp solution: BBH / SimCorp
About Brown Brothers Harriman
Brown Brothers Harriman (BBH) is a global financial services firm known for premium service and specialist expertise. For over 200 years, we have partnered with clients to navigate complexity, innovate with purpose, and succeed in evolving financial markets. Our 6,000 employees serve clients and their investments in over 90 markets across BBH’s 18 offices. As a private partnership, we are uniquely built to put clients first and create success that lasts.
BBH Investor Services is a leading provider of asset servicing and operating model solutions to global asset managers and financial institutions. Asset servicing solutions include custody, global tax services, depositary and trustee, accounting, administration, and transfer agency. Operating model solutions solve platform, data, and connectivity challenges across open-architecture operating models. We support clients’ growth, operational efficiency and resiliency, and streamline reporting and oversight. For more information see www.bbh.com.
About SimCorp
SimCorp is a provider of industry-leading integrated investment management solutions for the global buy-side. Founded in 1971, with more than 3,500 employees across five continents, SimCorp is a truly global technology leader that empowers more than half of the world’s top 100 financial companies through its integrated platform, services, and partner ecosystem.
SimCorp is a subsidiary of Deutsche Börse Group. As of 2024, SimCorp includes Axioma, the leading provider of risk management and portfolio optimization solutions for the global buy side. For more information, see www.simcorp.com.
About Quoniam
As a leading active, systematic asset manager, Quoniam manages assets totaling around 24 billion euros, employs over 120 people and has offices in Frankfurt and London.
Quoniam is not just systematic – it is science-based. We provide professional investors worldwide with smarter alpha and a more thoughtful way of investing, bringing clarity and precision to a complex world. For more information, visit www.quoniam.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128524490/en/
Contacts
BBH contacts
Gregory Kessler
Public Relations, BBH
+1 617-772-1265
Gregory.kessler@bbh.com
Prosek Partners
+1 857-302-3712
Pro-bbh@prosek.com
SimCorp contact
Sean B. Pasternak
Global Communications, SimCorp
+1 647-975-7326
sean.pasternak@simcorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom